Biosimilar Uptake Surges After Order Set Change at an Academic Center

Switching the default product in electronic order sets from originator biologics to preferred formulary biosimilars dramatically increased biosimilar utilization for commonly prescribed oncology infusion agents, according to a presentation from researchers at the University of Arkansas for Medical Sciences (UAMS).Those results offer a model for health-system pharmacists seeking to accelerate biosimilar adoption without a major overhaul to clinical workflows, said presenting author Sidney Keisner